Table 1.

Patient and clinical characteristics of study population

FactorsScreen detected (N = 247)Symptom detected (N = 603)P
Year at diagnosis
 1985–198934 (13.8)169 (28)<.001
 1990–199475 (30.4)192 (31.8)
 ≥1995135 (54.6)226 (37.5)
 Missing3 (1.2)16 (2.7)
Age at diagnosis, y
 40–4955 (22.3)201 (33.3)<0.01
 50–5982 (33.2)188 (31.2)
 60–7060 (24.3)130 (21.6)
 71–8750 (20.2)84 (13.9)
Ethnicity
 White193 (78.1)434 (72)0.13
 Black23 (9.4)85 (14)
 Hispanic30 (12.1)77 (12.8)
 Other1 (0.4)7 (1.2)
Tumor size, cm
 ≤2193 (78.1)300 (49.8)<0.001
 2–547 (19.1)260 (43.1)
 >51 (0.4)16 (2.7)
 Missing6 (2.4)27 (4.4)
Nodal status
 Negative160 (64.8)342 (56.7)0.06
 Positive84 (34)244 (40.5)
 Missing3 (1.2)17 (2.8)
Nuclear grade
 135 (14.2)52 (8.6)<0.01
 2131 (53)292 (48.4)
 362 (25.1)217 (36)
 Missing19 (7.7)42 (7)
Histology
 Invasive ductal225 (91.1)562 (93.2)0.22
 Invasive lobular20 (8.1)35 (5.8)
 Other2 (0.8)6 (1)
Ki67
 Low (<15%)126 (51)222 (36.8)<0.001
 High (≥15%)84 (34)307 (50.9)
 Missing37 (15)74 (12.3)
Tumor subtype
 Luminal A114 (46.2)170 (28.2)<0.001
 Luminal B48 (19.4)148 (24.5)
 HER2 positive29 (11.7)114 (18.9)
 Triple negative28 (11.3)126 (20.9)
 Missing28 (11.3)45 (7.5)
Chemotherapy
 None170 (68.8)290 (48.1)<0.001
 Anthracycline40 (16.2)205 (34)
 Anthracycline + taxane27 (10.9)72 (11.9)
 Other4 (1.7)13 (2.2)
 Missing6 (2.4)23 (3.8)
Hormone therapy
 Tamoxifen136 (55.1)254 (42.1)<0.01
 Other3 (1.2)17 (2.8) 
 None107 (43.3)321 (53.2)
 Missing1 (0.4)11 (1.8)

NOTE: All values are n (%).